# Featuring ACE2 binding SARS-CoV and SARS-CoV-2 through a conserved evolutionary pattern of amino acid residues

Patrícia P. D. Carvalho<sup>\*</sup> and Nelson A. Alves<sup>†</sup>

Departamento de Física, FFCLRP, Universidade de São Paulo, Avenida Bandeirantes, 3900. Ribeirão Preto 14040-901, SP, Brazil.

Spike (S) glycoproteins mediate the coronavirus entry into the host cell. The S1 subunit of S-proteins contains the receptor-binding domain (RBD) that is able to recognize different host receptors, highlighting its remarkable capacity to adapt to their hosts along the viral evolution. While RBD in spike proteins is determinant for the virus-receptor interaction, the active residues lie at the receptor-binding motif (RBM), a region located in RBD that plays a fundamental role binding the outer surface of their receptors. Here, we address the hypothesis that SARS-CoV and SARS-CoV-2 strains able to use angiotensin-converting enzyme 2 (ACE2) proteins have adapted their RBM along the viral evolution to explore specific conformational topology driven by the residues YGF to infect host cells. We also speculate that this YGF-based mechanism can act as a protein signature located at the RBM to distinguish coronaviruses able to use ACE2 as a cell entry receptor.

Keywords: SARS-CoV; SARS-CoV-2; ACE2; coronaviruses; receptor-binding domain; receptor-binding motif; evolutionary pattern

### I. INTRODUCTION

Viruses are the most numerous type of biological entity on Earth and the identification of novel viruses continues to enlarge the known viral biosphere [1, 2]. This collection of all viruses presents enormous morphological and genomic diversity as a result of continuous exchange of genetic material with the host cells [3, 4]. Moreover, this well succeeded long-term virus-host interaction indicates that viruses are more than simple genomic parasites in all cellular life forms [5]. A number of evidences has led to the proposal that viruses play an astonishing role as agents of evolution because of their capacity in propagating between biomes [6] and in gene transfer between species [7-10]. For this purpose, viruses have developed large number of genome replication and protein expression strategies to benefit from the host translational machinary over time [11].

Despite all of such enormous diversity in gene sequence, it is not possible to achieve huge number of highly distinct protein structures mainly because of stereochemical constraints on the possible protein folds [12]. In fact, it has been observed common secondary structures throughout different virus families while the sequences are not fully conserved [12, 13]. This may result in evolutionary efficiency once viruses can exploit already well designed motifs from similar cellular functions [11].

Currently, the world population is confronting a new coronavirus disease (COVID-19), a highly infectious disease to humans. This disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is affecting human health worldwide. Coronaviruses (CoVs) belong to the large and diverse family *Coronaviruse*, within the order *Nidovirales* and suborder

Cornidovirineae [14]. Their subfamily Orthocoronavirinae contains four genera based on phylogeny and termed as  $\alpha$ ,  $\beta$ ,  $\gamma$ , and  $\delta$ -coronavirus.

SARS-CoV-2 belongs to the  $\beta$ -coronavirus genus as well as SARS-CoV, middle east respiratory syndrome coronavirus (MERS-CoV), and hCoV-HKU1, to cite a few [15]. Other important representative human viruses as hCoV-NL63 and hCoV-229E belong to  $\alpha$ -coronavirus. Phylogenetic relationships among the known members of this subfamily indicate that  $\alpha$  and  $\beta$ -coronavirus infect mammals, while  $\gamma$  and  $\delta$ -coronavirus infect both mammalians and avians.

Members of *Coronaviridae* family are enveloped, positive single-stranded RNA (+ssRNA) viruses and render the largest genomes among all known RNA viruses [16– 19]. The +ssRNA genomes undergo rapid mutational changes [20], leading to faster adaptation to new hosts, though they also contain conserved sequence motifs as observed, for example, in multiple alignments do CoV strains [13, 21, 22].

Coronaviruses attach to host cell surface receptors via their spike (S) glycoproteins, located on the viral envelope, to mediate the entry into the host cell. Each monomer of trimeric S-protein comprises two subunits S1 and S2, responsible for the viral attachment and for the membrane fusion, respectively [23–25]. The S1 coronavirus subunit contains the receptor-binding domain (RBD) that is able to recognize different host receptors, highlighting its remarkable capacity to adapt to their hosts along the viral evolution. Thus, it is not unexpected to observe in this domain high sequence divergence even for the same coronavirus identified in different host species. In contrast, the S2 subunit presents the most conserved region in the S-protein.

The binding of RBD spike proteins to the receptor on the host cell is the first step in virus infection. This initial step is followed by an entry mechanism of enveloped viruses into target cells. Usually, most viruses enter cells

<sup>\*</sup> patricia.duzi.2018@usp.br

<sup>&</sup>lt;sup>†</sup> alves@ffclrp.usp.br

through endocytotic pathways with the fusion occurring in the endosomes, although a direct entry into cells can occur by fusion of their envelopes with the cell membrane [26].

A number of CoVs utilizes angiotensin-converting enzyme 2 (ACE2) as the entry receptor into cells, exemplified by  $\beta$ -genus human respiratory SARS-CoV, SARS-CoV-2, and  $\alpha$ -genus hCoV-NL63 [15, 27–29]. In particular, SARS-CoV, as well as SARS-CoV-2, enter the cell via endocytosis induced by RBD complexed with human ACE2 (hACE2) receptor [30–34]. In contrast, the  $\beta$ -genus MERS-CoV and its genetically related bat CoV-HKU4 utilize dipeptidyl peptidase 4 (DPP4) as the viral receptor [35]. Other viral receptor is aminopeptidase N (APN), recognized for example by the  $\alpha$ -genus hCoV-229E [36].

The human coronaviruses hCoV-HKU1, hCoV-229E, hCoV-NL63, and hCoV-OC43, cause mild to moderate upper respiratory tract infections [37], while SARS-CoV and SARS-CoV-2 cause severe respiratory diseases, with SARS-CoV-2 being far more lethal than SARS-CoV. SARS-CoV strains vary enormously in infectivity, which can be connected to their binding affinities to hACE2 [38]. This binding affinity, in turn, can be correlated with disease severity in humans [39].

While RBD in spike proteins is determinant for the virus-receptor interaction, the active residues lie at the receptor-binding motif (RBM), which is part of RBD and plays a fundamental role binding the outer surface of their receptors [27, 28, 38, 40, 41]. The importance of the RBM is further explored here in relation to its structural topology. Thus, instead of only analysing specific residues that make contacts with ACE2 after binding, we go a step further and track the molecular origin that drives the viral attachment to this cell receptor. This investigation has revealed a highly conserved amino acid residue sequence Tyr-Gly-Phe (YGF) in coronavirus variants that employ this receptor. Consequently, we hypothesize that the short sequence YGF is vital for RBD-ACE2 interaction because of the formation of a hydrophobic pocket proper to the receptor specificity [40, 42–44]. Moreover, we recognize that a similar binding mechanism is characteristic of the interaction between ubiquitin-associated (UBA) domain proteins and ubiquitin. In this vein, we conclude that is plausible that SARS-CoV and SARS-CoV-2 strains able to use ACE2 proteins have adapted their RBM along the viral evolution to explore such a mechanism to infect host cells.

### A. The conserved XGF loop in UBA-ubiquitin interaction

Amino acid sequences of type XGF, where the residue X is frequently the residue Met, form a highly conserved loop characteristic of ubiquitin-associated (UBA) domain that occurs in a variety of proteins. The UBA domain is a conserved motif through eukaryotic evolution and is found in many proteins related to the ubiquitin metabolism and in particular, associated with ubiquitinmediated proteolysis [45, 46]. The MGF loop in the UBA domain is typical of a hydrophobic pocket that is critical for recognition and binding affinity to ubiquitin through a hydrophobic surface patch located in the vicinity of this loop [47–54]. UBA domains are ubiquitin receptors whose binding is a fundamental step for diverse regulatory functions.

NMR analyses of UBA-ubiquitin interactions identify hydrophobic surface patches formed by the conserved MGF sequence as the main determinants for the proteinprotein interaction. A number of alignments of UBA domains has revealed mutations in the MGF sequence, mainly  $M\rightarrow$ L,  $M\rightarrow$ Q, and  $F\rightarrow$ Y, but these mutations still maintain the overall hydrophobic characteristic for the main set of residues located at the interface on these UBA domains [55, 56].

### II. RESULTS AND DISCUSSION

### A. Spike receptor-binding motifs in human CoVs

Here, we investigate the occurrence and importance of the specific amino acid residue sequence YGF for SARS-CoV and SARS-CoV-2 strains able to use ACE2 proteins as receptors. It is displayed in Fig 1a the interface of SARS-CoV RBD spike-protein (magenta and green color) complexed with hACE2 (blue color) to gain insight about the importance of this type of conformational mechanism in creating a shape complementarity between receptor and ligand. The RBM is in magenta color, with the yellow color displaying the YGFY sequence in that pocket, which establishes the proper relative position for favorable binding to surface-exposed hACE2 residues. The YGFY sequence seems strongly conserved in SARS-CoV spike RBD, more precisely located at residues 481-484 in the receptor binding motif. Noteworthy, this sequence seems to be unique because even the shorter YGF sequence does not occur in this region, neither in the RBD. As a consequence of this hydrophobic pocket, amino acid residues responsible for binding interaction are located close to this conformational structure as, for example, the residues N479 and T487 (Fig 2a). These residues have been identified to be essential for SARS-CoV spike RBD/ACE2 binding [39, 41, 57]. The residue N479 in SARS-CoV is located near K31 of hACE2 which in turn makes a salt bridge with E35, a residue buried in that hydrophobic environment. The residue T487 is located close to K353 on hACE2, and in turn makes a salt bridge with D38, also buried in that pocket. Other important residues for this attachment are Y442, L472, and D480 [40].

Figure 3a displays the residues of SARS-CoV RBM in direct contact with hACE2 as determined by the hydrophobic-hydrophilic properties of the interface residues as predicted by the CSU program [58]. This




Figure 1. Detailed surface view of SARS-CoV and SARS-CoV-2 RBD. (a) Residues YGFY at the interface of SARS-CoV complexed with hACE2 (PDB ID: 2AJF). These residues are in yellow color and form a hydrophobic pocket located in the RBM (magenta color). (b) Residues YGF and EGF (yellow color) at the interface of SARS-CoV-2 complexed with hACE2 (PDB ID: 6LZG). The first sequence is located in a hydrophobic pocket, while the second sequence EGF is on the RBM surface (magenta color). Ribbon representation of ACE2 is in blue color.




Figure 2. SARS-CoV and SARS-CoV-2/hACE2 RBD interfaces. Ribbon diagrams of SARS-CoV RBD (a) and SARS-CoV-2 RBD (b) complexed with hACE2 (blue color), where the RBM is highlighted in magenta color. The main residues responsible for the structural binding are displayed in the stick representation.

bipartite network of contacts highlights the importance of residues that are located near the YGF sequence and contributes to the stabilization of SARS-CoV complexed with hACE2. For example, Y475 makes hydrogen bond (H-B) contacts with Q24, F28, and Y83; N479 with K31, and H34; Y486 with Y41, N330, and R357; and T487 with Y41.

Figure 1b displays the interface of SARS-CoV-2 RBD spike-protein complexed with hACE2 (blue color). Now, the sequence YGFY observed in SARS-CoV is replaced




Figure 3. Contact networks between (a) SARS-CoV residues, and (b) SARS-CoV-2 residues located in the RBM regions with ACE2. SARS-CoV and SARS-CoV-2 residues are in magenta color while human ACE2 residues are in blue color.

		10	20	30	40	50	60	70	
SARS-CoV Tor2	424 NTRNIDA	A T S T <mark>GNYNY</mark> K	YRYLRHGKL	R P F E R D I S N V P	FSPDGKPCT	P-PALNCYWPL	ID YGFYT T	TGIGYOPY	494
SARS-CoV_BJ01	424 <mark>N T</mark> R N I <b>D</b> A	ΑΤS Τ <mark>GΝΥΝΥ</mark> Κ	YRYLRHGKL	R P F E R D I S N V P	FSPDGKPC1	P - PALNCYWPLM	IDYGFYT <mark>T</mark>	Τ <mark>ĠΙĠΥ<mark>Ϙ</mark>ΡΥ</mark>	494
SARS-CoV CUHK-W1	424 <mark>N T</mark> R N I D A	ΑΤS Τ <mark>GΝΥΝΥ</mark> Κ	YRYLRHGKL	R P F E R D I S N V P	F S P D G K P C 1	P - PALNCYWPLN	ID YGFY T <mark>T</mark>	Γ <mark>G I G Y Q P Y</mark>	494
SARS-CoV Urbani	424 <mark>N T</mark> R <mark>N I D</mark> A	ΑΤ S Τ <mark>G N Y N Y</mark> K	Y R Y L R H G K L	R P F E R D I S N V P	F S P D G K P C 1	P - PALNCYWPLN	IDYGFYT <mark>T</mark>	Τ <mark>ĠΙĠΥ<mark>Ϙ</mark>ΡΥ</mark>	494
SARS-CoV_Frankfurt-1	424 <mark>N T</mark> R <mark>N I D</mark> A	ΑΤ S Τ <mark>G N Y N Y</mark> K	Y R Y L R H G K L	R P F E R D I S N V P	F S P D G K P C 1	P - PALNCYWPLN	IDYGFYT <mark>T</mark>	T <mark>G I G Y <mark>Q P Y</mark></mark>	494
SARS-CoV CUHK-AG01	424 <mark>N T</mark> R <mark>N I D</mark> A	ΑΤ S Τ <mark>G N Y N Y</mark> K	Y R Y L R H G K L	R P F E R D I S N V P	F S P D G K P C 1	P - PALNCYWPLN	ID YGFY T <mark>T</mark>	Γ <mark>ĠΙĠΥ<mark>Ϙ</mark>ΡΥ</mark>	494
SARS-CoV TW6	424 <mark>N T</mark> R <mark>N I D</mark> A	ΑΤ S Τ <mark>G N Y N Y</mark> K	Y R Y L R H G K L	R P F E R D I S N V P	F S P D G K P C 1	<mark>P - PALNCYWP</mark> LN	I D Y G F Y T <mark>T</mark> <sup>-</sup>	T <mark>G I G Y <mark>Q P Y</mark></mark>	494
SARS-CoV_TW11	424 <mark>N T</mark> R <mark>N I D</mark> A	ΑΤ S Τ <mark>G N Y N Y</mark> K	Y R Y L R H G K L	R P F E R D I S N V P	F S P D G K P C 1	P - PALNCYWPLN	IDYGFYT <mark>T</mark>	T <mark>G I G Y <mark>Q P Y</mark></mark>	494
SARS-CoV HKU-39849	424 <mark>N T R N I D</mark> /	ΑΤ S T <mark>G N Y N Y</mark> K	YRYLRHGKL	R P F E R D I S N V P	F S P D G K P C 1	P - PALNCYWPLN	IDYGFYT <mark>T</mark>	Τ <mark>ĠΙĠΥ<mark>Ϙ</mark>ΡΥ</mark>	494
SARS-CoV-2 Wuhan-Hu-1	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	Y <mark>R</mark> L F <mark>R</mark> K S N L I	K P F E R D I S T E I	Y Q A <mark>G S T P C</mark> N	G V E G F N C Y F P L C	)	<mark>I G V G Y Q P Y</mark>	508
SARS-CoV-2_CA-CDC-0139	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	YRLFRKSNL	K P F E R D I S T E I	Y Q A <mark>G S T P C</mark> N	G V E G F N C Y F P L C	)                                    S	I G V G Y <mark>Q P</mark> Y	508
SARS-CoV-2 France/10009EE	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	Y <mark>R</mark> L F <mark>R K S N</mark> L I	K P F E R D I <mark>S T</mark> E I	Y Q A <mark>G S T P C</mark> N	G V E G F N C Y F P L C	)	<mark>I G V G Y Q P Y</mark>	508
SARS-CoV-2 WHUHnCoV011	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	YRLFRKSNL	K P F E R D I S T E I	Y Q A <mark>G S T P C</mark> N	GVEGFNCYFPLC	)	I G V G Y <mark>Q P</mark> Y	508
SARS-CoV-2_CA-CZB-1248	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	YRLFRKSNL	K P F E R D I S T E I	Y Q A <mark>G S T P C</mark> N	G V E G F N C Y F P L C	)	I G V G Y <mark>Q P</mark> Y	508
SARS-CoV-2 CA-CZB-1033	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	Y <mark>R</mark> L F <mark>R K S N</mark> L I	K P F E R D I <mark>S T</mark> E I	Y Q A <mark>G S T P C</mark> N	G V E G F N C Y F P L C	)	<mark>I G V G Y Q P Y</mark>	508
SARS-CoV-2 France/10070SK	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	YRLFRKSNL	K P F E R D I S T E I	Y Q A <mark>G S T P C</mark> N	GVEGFNCYFPLC	)	I G V G Y <mark>Q P</mark> Y	508
SARS-CoV-2_CA-CZB0103	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	Y <mark>R</mark> L F <mark>R K S N</mark> L I	K P F E R D I <mark>S T</mark> E I	Y Q A <mark>G S T P C</mark> N	GVEGFNCYFPLC	)	<mark>I G V G Y Q P Y</mark>	508
SARS-CoV-2_Wuhan/IPBCAMS-WH-05	5 437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	YRLFRKSNL	K P F E R D I S T E I	YQAGSTPCN	G V E G F N C Y F P L C	)	I G V G Y <mark>Q P</mark> Y	508
SARS-CoV-2 CruiseA-18	437 <mark>N S N N L D</mark> S	SKV <mark>GGNYNY</mark> L	Y <mark>R</mark> L F <mark>R</mark> K S N L I	K P F E R D I S T E I	Y Q A <mark>G S T P C</mark> N	G V E G F N C Y F P L C	)	<mark>I G V G Y Q P Y</mark>	508
SARS-CoV-2_CA-CZB-1105	437 <mark>N S N N L D</mark> S	K V <mark>G G N Y N Y</mark> L	YRLFRKSNL	K P F E R D I S T E I	YOAGSTPCN	GVEGFNCYFPLC	SYGF <mark>OP</mark> TN	IGVGYOPY	508

Figure 4. Sequence alignments of human CoVs restricted to RBM residues. The medium purple color highlights the YGFY pattern followed by the mutation Y498Q in the RBM of SARS-CoV-2 strains.

by YGFQ as a result of sequence alignments shown in Fig 4. The single-point mutation Y484 $\rightarrow$ Q498 replaces a hydrophobic residue in SARS-CoV by a hydrophilic one in SARS-CoV-2.

Figure 4 compares residue sequences of human SARS-CoV and SARS-CoV-2 strains aligned with RBM of SARS-CoV Tor2, an epidemic strain isolated from humans during the SARS epidemic in 2002-2003. The human Tor2 strain has high affinity for hACE2 [38]. We highlight in this figure in medium purple color the hydrophobic sequence YGFY typical of SARS-CoV, occur-

ring at positions 481-484 in the spike protein. The corresponding mutated sequence occurs now at positions 495-498 in SARS-CoV-2 spike protein.

The important residues for the interface interaction found in SARS-CoV are mutated in SARS-CoV-2. The sequence alignments show the mapping, Y442 $\rightarrow$ L455, L472 $\rightarrow$ F486, N479 $\rightarrow$ Q493, D480 $\rightarrow$ S494, and T487 $\rightarrow$ N501. These mutations do not present a drastic change in their hydrophobic character [59], thus preserving the overall receptor-binding topological structure for these viruses. In particular, residues L455 and Q493 in SARS-CoV-2 preserve the noted favourable interactions with the residues E35 and K31 in hACE2 [60] (Fig 2b). Interestingly, a new GF sequence appears in the RBM of SARS-CoV-2 strains as a consequence of the mutation L472 $\rightarrow$ F486, producing a small hydrophobic surface, but does not seem to disrupt the proposed topological formation mechanism for ACE2 binding. No other GF sequence appears in their RBD.

Figure 3b displays the SARS-CoV-2 RBM residues in direct contact with hACE2 as predicted by the CSU program, showing again the importance of residues close to the hydrophobic pocket. Details of protein-protein binding interfaces can be quite different among strains, likely related to their infectivity degree. It has been noted that mutations in RBM residue T487 in SARS-CoV have an important role in the human-to-human and animal-tohuman transmission of SARS-CoV [36, 38, 57].

Now, we investigate the relevance of the hydrophobic pocket driven by the YGFY sequence in promoting the stability of SARS-CoV spike receptor binding domain complexed with hACE2. To this end, we conducted a series of mutations to estimate the change in binding affinity  $\Delta\Delta G$  using the MutaBind2 method [61].

Initially, we investigate the influence of N479 mutation by the residues E, K, Q, R, and S on the complexation. The mutations N479E, N479K, N479Q, N479R, and N479S have been observed, respectively in pangolin strains (see Fig. 6), bat and palm civet strains (see Fig. 5 and 6), human SARS-CoV-2 (see Fig. 4), bat and palm civet strains (see Fig. 5 and 6), and bat strains (see Fig. 5). The calculation of  $\Delta\Delta G$  for these mutations does not indicate any appreciable effect on SARS-CoV spike RBD/hACE2 binding affinity due to its small variation, as displayed in Table I. Therefore, we may conclude that N479 does not enhance the binding affinity of spike RBD to hACE2, and could as well be replaced by any of the above residues, preserving the hydrophilic character [59] and conformational stability.

Specific mutations were also performed to investigate the importance of the residues forming the hydrophobic surface patch for the complexation stability. Residues Y481 and F483 are conserved through all SARS-CoV strains we have analysed in this work, while G482 and Y484 are mutated in some strains (bats and pangolins). Therefore, we mutated G482 and F484 by plausible residues, i.e., the ones that occur in other strains to evaluated the changes in the binding affinity. To perform this double mutation, we fixed G482D, a mutation observed in bat strains, followed by Y484F, Y484N, and Y484T, observed in bats; Y484H, observed in pangolins; and Y484Q, observed in human SARS-CoV-2. The freeenergy changes for these double mutations strongly indicate the desestabilization of human SARS-CoV complexed with hACE2 (Table I). It is interesting to note that G482D together with Y484Q decreases the binding affinity in human SARS-CoV because they decrease the hydrophobicity of the initial YGFY pocket. Table I also displays the changes in binding affinity for single muta-

	$\Delta\Delta G$	Effect on the
SARS-CoV	(kcal/mol)	complexation
N479E	0.76	neutral $^{(2)}$
N479K	0.66	neutral $^{(2)}$
N479Q	0.40	neutral $^{(2)}$
N479R	0.08	neutral $^{(2)}$
N479S	0.63	$neutral^{(2)}$
G482D, Y484F	2.40	highly destabilizing <sup>(2)</sup>
G482D, Y484H	2.68	highly destabilizing <sup>(2)</sup>
G482D, Y484N	3.24	highly destabilizing <sup>(2)</sup>
G482D, Y484Q	2.47	highly destabilizing $^{(2)}$
G482D, Y484T	3.26	highly destabilizing $^{(2)}$
Y484F	0.64	$neutral^{(**)}$
Y484H	1.57	highly destabilizing $^{(1)}$
Y484N	2.19	highly destabilizing $^{(1)}$
Y484Q	1.44	neutral <sup>(*)</sup>
Y484T	1.92	highly destabilizing $^{(1)}$
N479E, G482D, Y484F	4.58	highly destabilizing $^{(2)}$
N479E, G482D, Y484H	4.90	highly destabilizing <sup>(2)</sup>
N479E, G482D, Y484N	4.69	highly destabilizing <sup>(2)</sup>
N479E, G482D, Y484Q	4.58	highly destabilizing <sup>(2)</sup>
N479E, G482D, Y484T	4.67	highly destabilizing $^{(2)}$
SARS-CoV-2		
Q498Y	0.16	neutral $^{(2)}$
G496D, Q498F	2.75	highly destabilizing <sup>(2)</sup>
G496D, Q498H	2.52	highly destabilizing <sup>(2)</sup>
G496D, Q498N	1.72	highly destabilizing <sup>(1)</sup>
G496D, Q498T	1.68	highly destabilizing $^{(1)}$
Q493S	0.89	$neutral^{(*)}$
Q493S, G496D, Q498F	3.63	highly destabilizing <sup>(2)</sup>
Q493S, G496D, Q498H	4.33	highly destabilizing $^{(2)}$
Q493S, G496D, Q498N	2.96	highly destabilizing $^{(2)}$
Q493S, G496D, Q498T	2.85	highly destabilizing $^{(2)}$

Table I. Changes in binding affinity of human SARS-CoV and human SARS-CoV-2 spike RBD complexed with hACE2 upon mutation as predicted by MutaBind2 method. Prediction effects are classified as low-confidence prediction: (1), or highconfidence prediction: (2). Here we adopt the classification presented in MutaBind method [62] because of the high similarity between the ROC (receiver operating characteristic) curves in both methods.

tions of Y484, a highy connected residue with hACE2 (see Fig. 3).

Next, we mutated N479 followed by mutations at sites 482 and 484 to analyse the consequences on the binding affinity of this triple mutation by disrupting the hydrophobic surface patch. Again, we fixed, for example, the mutations N479E and G482D. The impacts of this set of mutations can be seen in Table I. What was considered to be a neutral mutation, N479E shows high destabilizing effect in the new conformational environment. Similar destabilizing effects on the human SARS-CoV spike RBD complexed with hACE2 are obtained for the important residue T487 when one mutates the residues forming

SARS-CoV Tor2	424 <mark>N T</mark> RN		KYRYLRHGK				WPLNDYGFY TTGIGYOP	494
Rhinolophus affinis CoV LYRa3							WPLNDYGFY TTNGIGYOP	
Rhinolophus affinis CoV LYRa11							WPLNDYGFY TTNGIGYOP	
Bat SARS-like CoV Rs3367							WPLNDYGFY I TNG I GYOP	
Bat SARS-like CoV Rs4874	424 <mark>N T</mark> RN	I DA TO TGN YN	KYRSLRHGK	LRPFERDIS	N V P F S P D G K P O	TP - PAFNCY	WPLNDYGFY I TNG I GYOP	494
Bat SARS-like CoV WIV1							WPLNDYGFY   TNG   GYOP	
SARS-like CoV WIV16	424 <mark>N T</mark> RN	I DA TO T <mark>GN Y</mark> N Y	KYRSLRHGK	LRPFERDIS	N V P F S P D G K P C	CT <mark>P - P</mark> AF <mark>N</mark> CY	WPLNDYGFY I TNG I GYOP	494
Bat CoV RaTG13	437 <mark>N S</mark> КН	IDAKEGGNEN	LYRLFRKAN	LKPFERDIS	TEIYOAGSKP	CNGOTGLNCY	Y P L Y R Y G F Y <mark>P T</mark> D <mark>G V G H Q P</mark> Y	۲ 508
Bat SARS-like CoV Rs7327	425 <mark>N T</mark> RN	I D A T S T G N Y N Y	KYRSLRHGK	LRPFERDIS	N V P F S P D G K P C	CTP-PAFNCY	WPLNDYGFFTTNGIGYOP	495
Bat SARS-like CoV Rs9401	425 <mark>N T</mark> RN	I <mark>D</mark> A T S T <mark>G N Y</mark> N Y	K Y R S L R H G K	LRPFERDIS	N V P F S P D G K P (	C T <mark>P - P</mark> A F <mark>N</mark> C Y \	WPLNDYGFFT <mark>T</mark> N <mark>GIGYQ</mark> P	495
CoV BtRs-BetaCoV/YN2018B	425 <mark>N T</mark> RN	I <mark>D</mark> A T S T <mark>G N Y</mark> N Y	KYRSLRHGK	LRPFERDIS	N	C T <mark>P - P</mark> A F <mark>N</mark> C Y \	W <mark>P L N D Y G F F T T N G I G Y Q P</mark> Y	495
Bat SARS-like CoV RsSHC014	425 <mark>N T</mark> N S I	< D S S T S G N Y N Y	LYRWVRRSK	LNPYERDLS	N <mark>D</mark> I Y S <mark>P G G</mark> Q S (	CSA-V <mark>GPN</mark> CY	N P L R P Y G F F T T A G V G H Q P Y	495
Bat SARS-like CoV Rs4084	425 <mark>N T</mark> N S I	< <mark>D</mark> S S T S <mark>G N Y</mark> N	LYRWVRRSK	LNPYERDLS	N <mark>D</mark> I Y S <mark>P G G</mark> Q S (	CSA-V <mark>gpn</mark> cy	N P L R P Y G F F T <mark>T</mark> A <mark>G V G H Q P</mark> Y	495
Bat SARS-like CoV Rs4231	424 <mark>N T</mark> N S I	< <mark>D</mark> S S T S <mark>G N Y</mark> N Y	LYRWVRRSK	LNPYERDLS	N <mark>D</mark> I Y S <mark>P G G</mark> Q S (	CSA-I <mark>gpn</mark> cy	N P L R P Y G F F T <mark>T</mark> A <mark>G V G H Q P</mark> Y	494
SARSr-CoV BtKY72	428 <mark>N T</mark> N S V	√ <mark>D</mark> S K - S <mark>G N</mark> - N F	YYRLFRHGK	IKPYERDIS	N V L Y N S A <mark>G G</mark> T (	C S S I S Q L <mark>G</mark> C <mark>Y</mark> I	E <mark>PLKSYGFT<mark>PT</mark>V<mark>GVGYQP</mark>Y</mark>	497
SARS-like CoV BB9904/BGR/2008	432 <mark>N T</mark> N A I	_ <mark>D</mark> S <mark>N</mark> K D F	YYRLFRHGK	IKPYGRDLS	N	5 T - I N <u>N</u> L <mark>N</mark> C <b>F</b> /	4 <mark>P L K S Y G F</mark> T Q <mark>S </mark> S <mark>G I S F Q P</mark> Y	498
Bat_CoV_BM48-31/BGR/2008	429 <mark>N T</mark> N S I	_ <mark>D</mark> S S <mark>N</mark> - E F	FYRRFRHGK	IKPYGRDLS	N V L F N <mark>P</mark> S <mark>G G</mark> T (	C S A - E <mark>G</mark> L <mark>N</mark> C <mark>Y</mark> I	۲	495
CoV_BtRI-BetaCoV/SC2018							Y T L S T Y D F N <mark>P</mark> N V <mark>P V A Y Q</mark> A <sup>-</sup>	
BtRs-BetaCoV/HuB2013							Y T L S T Y D F N <mark>P</mark> N V <mark>P</mark> V A <mark>Y Q</mark> A <sup>-</sup>	
Bat SARS-CoV HKU3-1	428 <mark>N T</mark> AKH	+ <mark>D</mark> T <mark>G N Y</mark> - <mark>)</mark>	' -	LKPFERDLS	S <mark>D</mark> D <mark>G</mark>	· <mark>NG</mark> V`	Y T L S T Y D F N <mark>P</mark> N V <mark>P V A Y Q</mark> A <sup>-</sup>	F 481
Bat SARS-like CoV bat-SL-CoVZC45							R T L S T Y D F N <mark>P</mark> N V <mark>P</mark> L E <mark>Y Q</mark> A <sup>-</sup>	
Bat_SARS-like_CoV_bat-SL-CoVZXC21							R T L S T Y D F N <mark>P</mark> N V <mark>P</mark> L E <mark>Y Q</mark> A <sup>-</sup>	
Bat_SARS-CoV_Rf1/2004							R T L S T Y D F N <u>Q</u> N V <mark>P</mark> L E <mark>Y Q</mark> A <sup>-</sup>	
Bat SARS-like CoV Rf4092							R T L S T Y D F N <mark>P</mark> N V <mark>P</mark> L D <mark>Y Q</mark> A <sup>-</sup>	
Bat CoV Anlong-103							R T L S T Y D F N <mark>P</mark> Y V <mark>P</mark> L D <mark>Y Q</mark> A <sup>-</sup>	
Bat_CoV_Anlong-112							R T L S T Y D F N <mark>P Y</mark> V <mark>P</mark> L D <mark>Y Q</mark> A <sup>-</sup>	
Bat_SARS-CoV_Rp3/2004							R T L S T Y D F Y <mark>P S</mark> V <mark>P V A Y Q</mark> A <sup>-</sup>	
CoV_BtRs-BetaCoV/YN2018C							R T L S T Y D F Y <mark>P T</mark> V <mark>P I E Y Q</mark> A <sup>-</sup>	
Bat CoV Rp/Shaanxi2011							Y T L S T Y D F Y <mark>P S</mark> V <mark>P</mark> L D <mark>Y Q</mark> A <sup>-</sup>	
Bat SARS-CoV Rm1/2004	428 <mark>N T</mark> AQO	QDQ GQY - 1	- <b>Y R S Y R</b> K E <b>K</b>	LKPFERDLS	S <b>D</b>	E <mark>NG</mark> V	Y T <mark>L</mark> S TYD F Y <mark>P S</mark> I <mark>P</mark> V E <mark>Y Q</mark> A <sup>-</sup>	r 480
SARS-CoV-Tor2	424 <mark>N T</mark> RN	I DATST <mark>GNY</mark> N	KYRYLRHGK	LRPFERDIS	N V P F S P D G K P C	CTP-PALNCY	W <mark>PLNDYGFY</mark> T <mark>TGIGYQP</mark> Y	494
Bat CoV RaTG13	437 <mark>N S</mark> K H	IDAKEGGNFN	LYRLFRKAN	LKPFERDIS	ΤΕΙΥΟΑGSΚΡΟ	CNGQTGLNCY	Y <mark>P L Y R Y G F Y P T</mark> D <mark>G V G H Q P</mark> Y	Ý 508
SARS-CoV-2_Wuhan-Hu-1							F <mark>PL</mark> QS <mark>YGF</mark> Q <mark>PT</mark> N <mark>GVGYOP</mark> Y	

Figure 5. Sequence alignment of bat CoVs restricted to RBM residues of SARS-CoV Tor2. The residues of YGFY pattern are in medium purple color. Last three alignments are placed together for direct amino acid sequence comparison.

the hydrophobic pocket (data not shown).

Now, we repeat the above procedure to investigate the role of residues YGFQ for human SARS-CoV-2 RBD/hACE2 binding affinity. The mutation Q498Y does not alter the binding affinity for the complexation because the predicted  $\Delta\Delta G$  is about 0.16 kcal/mol. We also analysed the impact of double mutations in the YGFQ sequence on the stability of the complexation, see Table I. To this end, we fixed, for example G496D and replaced Q498 by the residues F, H, N, and T that appear in strains of other species. The predicted changes in binding affinity by mutations indicate destabilization of new complexations.

### B. Spike receptor-binding motifs in bats

It is known that not all SARS-CoV strains isolated from bat hosts have exploited ACE2 as a cellular attachment. Therefore, the set of amino acid sequences displayed in Fig 5 may exemplify the successful relation between virus evolution and the binding mechanism. This set highlights in medium purple color the preserved amino acid residues in the sequence YGFY, characteristics of human SARS-CoV. For comparison, we also display CoV strains with mutations in that SARS-CoV pattern to explore the relation between the hypothesized mechanism and the cell receptor recognition.

It has been demonstrated that LYRa11 [28], Rs3367 [63], Rs4874 [64], WIV1, and WIV16 [28, 65], have the capacity to use ACE2 for cell entry as well RaTG13, in line

with our hypothesis. Also, the near single-point mutation  $Y \rightarrow F$  in the next six strains Rs7327, Rs9401, YN2018B, RsSHC014, Rs4084, and Rs4231, does not interfere, as expected, in the attachment mechanism. This conclusion is supported by cell entry studies for Rs7327 [28, 64], Rs9401, RsSHC014, Rs4084, and Rs4231 [64], because they are in a group that is likely to use the ACE2 receptor. This mutation replaces a hydrophobic residue by another one with higher hydrophobicity, reinforcing the conformational topology for binding with the receptor. This single-point mutation  $Y \rightarrow F$  in human SARS-CoV produced a neutral effect in the binding hACE2 (Table I).

We identified in the next group constituted by BtKY72, BB9904/BGR/2008. and BM48-31/BGR/2008, respectively the mutations Y487T. Y488T, and Y485T, decreasing the initial hydrophobicity of the expected pocket in these strains. It seems unlikely that this mutation and amino acid residue deletions associated to Tor2 RBM sequence affect the YGF-based attachment mechanism for BtKY72 and BB9904/BGR/2008. Unfortunately, there is no available experimental data concerning their receptors. It is important to remark that the residue F492 in BM48-31/BGR/2008 produces another hydrophobic sequence IGF at residues 490-492 (Fig 5). We speculate that this double occurrence may disrupt the aforementioned mechanism because of indications that BM48-31/BGR/2008 does not interact, at least with human ACE2 [28]. No other GF sequence occurs in the RBD of these strains.

SARS-CoV_Tor2	424 N TRN I D A TS TGN YN Y KY RYL RHGKL RPFERD I SN V PF SPDGKPC TP - PALNCY WPL ND Y G FY TTTG I G Y O PY 494	F
SARS-CoV_PC4-115	424 N TRN I DA TS TGNYNY KYRYL RHGKL RPFERD I SNVPF SPDGKPC TP - PAPNCYWPLNGYGFY TTSG I GYQPY 494	F
SARS-CoV_PC4-145	424 N TRN I D A TS TGN YN Y KY RYL RHGKL RPFERD I SN V PF SPDGK PC TP - PAPNCYWPL NG YGFY TTSG I GY QPY 494	F
SARS-CoV_PC4-241	424 N TRN I DA TS TGNYNY KYRYL RHGKL RPFERD I SNVPF SPDGKPC TP - PAPNCYWPLNGYGFY TTSG I GYQPY 494	F
SARS-CoV_civet014	424 N TRN I DATS TGNYNYKY RYL RHGKL RPFERD I SNVPF SPDGK PC TP - PAPNCYWPL KGYGFY TTSG I GYQPY 494	ł
SARS-CoV_PC4-137	424 N TRN I D A TS TGN Y NY KY RY L RHGK L RPFERD I SN V PF SPDGK PC TP - PAPNCY WPL KGY GFY TTSG I GY QPY 494	ł
SARS-CoV_civet020	424 N TRN I D A TS TGN Y NY KY RY L RHGK L RPFERD I SN V PF SPDGK PC TP - PAPNCY WPL RGY GFY TTSG I GY QPY 494	F
SARS-Cov_PC4-127	424 N TRN I DA TS TGNYNY KYRYL RHGKL RPFERD I SNVPF SPDGKPC TP - PAPNCYWPL RGYGFY TTSG I GYQPY 494	F
SARS-CoV B039	424 N TRN I D A TS TGN YN Y KY RY L RHGKL RPFERD I SN V PF SPDGK PC TP - PAPNC YWPL RGYGFY TTSG I GY QPY 494	ł
SARS-CoV_PC4-205	424 N TRN I D A TS TGN Y NY KY RY L RHGK L RPFERD I SN V PF SPDGK PC TP - PAPNCY WPL RGY GFY TTSG I GY Q PY 494	ł
SARS-CoV_PC4-199	424 N TRN I D A TS TGN Y NY KY RY L RHGK L RPFERD I SN V PF SPDGK PC TP - PAPNCY WPL RGY GFY TTSG I GY QPY 494	۴
SARS-CoV_civet010	424 N TRN I DA TS TGNYNY KYRYL RHGKL RPFERD I SNVPF SSDGKPC TP - PAPNCYWPL RGYGFY TTSG I GYQPY 494	F
SARS-CoV civet019	424 N TRN I D A TS TGN YN Y KY RY L RHGKL RPFERD I SN V PFSSDGK PC TP - PAPNCYWPL RGYGFY TTSG I GY QPY 494	ł
SARS-CoV_A022	424 N TRN I D A TS TGN YN Y KY RY L RHGKL RPFERD I SN V PFSSDGK PC TP - PAPNCYWPL RGYGFY TTSG I GY QPY 494	ł
SARS-CoV_007/2004	424 N TRN I D A TS TGN Y NY KY RY L RHGK L RPFERD I SN V PFSSDGK PC TP - PAPNCY WPL RGY GFY TTSG I GY Q PY 494	ł
SARS-CoV_A001	424 N TRN I D A TS TGN Y NY K X RY L RHGK L RPFERD I SN V PF SP X GK PC TP - PAPNC Y WPL RGY GFY TTSG I GY Q PY 494	F
PCoV GX-P2V	437 N S V K Q D A L T G G N Y G Y L Y R L F R K S K L K P F E R D I S T E I Y Q A G S T P C N G Q V G L N C Y Y P L E R Y G F H P T T G V N Y Q P F 508	\$
PCoV_GX-P4L	435 N S V K Q D A L T G G N Y G Y L Y R L F R K S K L K P F E R D I S T E I Y Q A G S T P C N G Q V G L N C Y Y P L E R Y G F H P T T G V N Y Q P F 506	j
PCoV_GX-P5L	435 N S V K Q D A L T G G N Y G Y L Y R L F R K S K L K P F E R D I S T E I Y Q A G S T P C N G Q V G L N C Y Y P L E R Y G F H P T T G V N Y Q P F 506	ز
SARS-CoV-2 Wuhan-Hu-1	437 N SNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYOAGSTPCNGVEGFNCYFPLOSYGFOPTNGVGYOPY 508	\$

Figure 6. Sequence alignment of palm civet CoVs and pangolin PCoVs restricted to RBM residues of SARS-CoV Tor2. The residues of YGFY pattern are in medium purple color. Last line includes the SARS-CoV-2 sequence for comparison.

Next CoV strains in Fig 5 do not contain such specific YGF sequences of residues in the RBM neither in their RBD. We find the two-letter sequence GF in Rf1/2004, but it is located in RBD and with GF surrounded by hydrophilic residues. Although we have considered only part of the sequences that better align with RBM of Tor2, it has been demonstrated that the spikes of HuB2013, HKU3, CoVZC45, CoVZXC21, Rf1, Rf4092, and Shaanxi2011 do not use hACE2, a result that is not just a consequence of deletions at the RBD [28]. Further support has been presented against HKU3 in using hACE2 [66]. It seems unlikely that Rm1/2004 infects hACE2 because its unfavourable binding free energy [67]. Another result concludes that Rp3 is unable of infect hACE2 or even bat ACE2 [68].

We have placed together the alignments involving Tor2, RaTG13, and SARS-CoV-2 at the end of Fig 5 for further comparison. The whole genome of RaTG13 shares 96% amino acid sequence identity with SARS-CoV-2, and it is considered the most closely related genome to this CoV [69]. Considering its spike protein, and RBM, RaTG13 shares respectively 97% and 76% amino acid identity with SARS-CoV-2. For comparison, RaTG13 shares 79%, 77%, and 53% identity, respectively, for the whole genome, spike protein, and RBM with SARS-CoV Tor2. Therefore, SARS-CoV-2 is mostly similar to RaTG13 than SARS-CoV strains in all regions.

### C. Spike receptor-binding motifs in palm civets and pangolins

To explore further the role of YGF-based attachment mechanism, we exhibit comparative residue sequences for civet and pangolins, again aligned with RBM of SARS-CoV Tor2 (Fig 6). This figure shows that the pattern YGFY characteristic of human SARS-CoV is maintained for the collected data, but with a single-point mutation  $Y \rightarrow H$  for pangolin hosts PCoV. It is worth to observe that even the shorter two-letter GF sequence is not found in the RBD of these strains, which could promote another hydrophobic pocket.

We have included SARS-CoV-2 on the last line of Fig 6 for a direct comparison. PCoV GX-P2V shares 79%, 77%, and 50% amino acid identity with Tor2, respectively for whole genome, spike protein, and RBM aligned with Tor2. In relation to SARS-CoV-2, PCoV GX-P2V shares 85%, 92%, and 75% amino acid identity, respectively for whole genome, spike protein, and RBM. It is believed that human SARS-CoV passed from palm civets to humans in the 2002-2003 epidemic because their genome sequences are highly similar [38, 57, 70]. The amino acid alignments show an almost identical RBM between human SARS-CoV, represented by Tor2 strain, and collected data from palm civet strains. This identification also includes the YGF-based mechanism able to use ACE2 proteins. Nevertheless, these alignments display high similarity between pangolins and SARS-CoV-2, which also support previous conclusions on pangolins being the probable origin of SARS-CoV-2 [69, 71]. However, based on our data related to host receptor binding and their RBM and S-protein alignments, we can not discard bat RaTG13-like strain as also the possible origin of SARS-CoV-2.

# D. SARS-CoV and hCoV-NL63: only functionally related

Although there is no many available experimental data identifying the viral receptor-binding protein for CoVs, it is well established that human SARS-CoV and hCoV-NL63 both employ ACE2 as the cell receptor to infect host cells [72, 73]. Interestingly, SARS-CoV and hCoV-NL63 domains do not present high sequence similarity. For example, their spike-S1 subunities share only 10% in similarity. Other features separate SARS-CoV and hCoV-NL63 [74]. SARS-CoVs are classified as  $\beta$ -coronavirus with subgenus sarbecovirus, while hCoV-NL63 is in genus  $\alpha$ -coronavirus and subgenus setracovirus. Although hCoV-NL63 also enters the cell via endocytosis, its functional receptor requires heparan sulfate proteoglycans for the initial attachment, representing an important extra factor for ACE2 to act as a functional receptor [33, 74]. Moreover, the spike-S1 glycoprotein of SARS-CoV binds more efficiently ACE2 than the corresponding spike-S1 of NL63 (NL63-S) [75]. This may be linked to the fact that SARS-CoV and NL63-S contact ACE2 differently, a conclusion based upon the experimental results that NL63-S does not bind to ACE2 through a single and large domain [73, 76]. Actually, different RBD regions have been identified within NL63-S. One of these regions was positioned at residues 476-616 and comprising three discontinuous RBM regions, RBM1 (residues 497-501), RBM2 (residues 530-540), and RBM3 (residues 575-594) [77–79]. A slightly different RBD has been identified for this CoV [76]. It would be located at residues 482-602, also with three discontinuous RBM regions, which surround a shallow cavity at hCoV-NL63-ACE2 binding interface. Curiously, its spike protein alignment with Tor2 does not show the expected residue pattern in the corresponding RBM of Tor2 nor in the aforementioned RBD regions of NL63-S. This may help to explain the unusual pathway of binding to ACE2 for this CoV.

### III. METHODS

We performed single and multiple residue mutations to estimate the importance of the conserved residues in human SARS-CoV and SARS-CoV-2 RBM forming the hydrophobic pocket in establishing specific interactions with hACE2. Mutations may affect the spike receptorbinding complexed with hACE2 either leading to higher, lower or even neutral binding affinity. Thus, we apply the fast and accurate MutaBind2 method [61] to estimate the binding free-energy change  $\Delta\Delta G = \Delta G^{\mbox{mut}} - \Delta G^{\mbox{wt}}$ upon mutation to predict its functional effects. This method compares free-energy changes between mutated and wild-type three-dimensional conformations. The binding free-energy change upon single mutation was also evaluated with the predictor BeAtMuSiC [80] based on a set of statistical potentials extracted from experimental mutational data. This computational method predicted very similar effects on the complexation (data

not shown) as described in Table I.

### **Bioinformatic tools**

We have also used the bioinformatic tools BLAST and ClustalW for sequence alignment and analysis of CoV strains, and Jalview to examine and edit various sequence alignments. Figures showing the conformational complexations were prepared using PyMol. The list of Gen-Bank accession codes for the spike proteins analysed in this work is available in supplementary Table S1.

### IV. CONCLUSION

We have analysed a number of CoV strains to support the hypothesis that SARS-CoV and SARS-CoV-2 strains share a common evolutionary mechanism for the initial attachment to ACE2. Moreover, we speculate that the YGF-based mechanism can act as a protein signature to distinguish CoVs able to use ACE2 as a cell entry receptor whenever this residue sequence is located at the CoV RBM region. For example, bat-SL-CoV ZC45 and ZXC21 are closely related sequences to SARS-CoV-2 with overall genome identity of  $\sim 89\%$  and can be promptly put under suspicious in their ACE2 binding affinity because the lack of such signature. Of course, as exemplified by hCoV-NL63, we can not discard that another mechanism can act helping such ACE2 binding. It must be accentuated that the occurrence of other XGF sequences, mainly with X being a hydrophobic residue, in the RBM, or even in the RBD region, can disrupt the proposed topological mechanism for ACE2 binding. This because it might introduce hydrophobic loops promoting a new ligand-substrate recognition.

## V. SUPPORTING INFORMATION

Table S1 GenBank accession numbers for the coronavirus sequences analysed in this study.

#### Acknowledgements

P.P.D.C. and N.A.A. gratefully acknowledge financial supports from the Brazilian agencies CAPES, and FAPESP, process 2015/16116-3, respectively.

**Competing interests** The authors declare no competing financial interests.

 Pan, D., Nolan J., Williams K.H., Robbins M.J., Weber K.A., 2017. Abundance and distribution of microbial cells and viruses in an alluvial aquifer. Front Microbiol 8, 1199. https://doi.org/10.3389/fmicb.2017.01199

[2] Shi, M., Lin, X.-D., Chen, X., Tian, J.-H., Chen, L.-J., Li, K., et al., 2018. The evolutionary history of vertebrate RNA viruses. Nature 556, 197-202. https://doi.org/10.1038/s41586-018-0012-7

- [3] Nasir, A., Forterre, P., Kim, K.M., Caetano-Anollés, G., 2014. The distribution and impact of viral lineages in domains of life. Front Microbiol 5, 194. https://doi.org/10.3389/fmicb.2014.00194
- [4] Koonin, E.V., Dolja, V.V., Krupovic, M., Varsani, A., Wolf, Y.I., Yutin, N., et al., 2020. Global organization and proposed megataxonomy of the virus world. Microbiol Mol Biol Rev 84, e00061-19. https://doi.org/10.1128/MMBR.00061-19
- [5] Claverie, J.M., 2006. Viruses take center stage in cellular evolution. Genome Biol 7, 110. https://doi.org/10.1186/gb-2006-7-6-110
- [6] Sano, E., Carlson, S., Wegley, L., Rohwer, F., 2004. Movement of viruses between biomes. Applied Environmental Microb 70, 5842-5846. https://doi.org/10.1128/aem.70.10.5842-5846.2004
- [7] Van Blerkom, L.M., 2003. Role of viruses in human evolution. Yearbook Phys Anthropology 46, 14-46. https://doi.org/10.1002/ajpa.10384
- [8] Filée, J., Forterre, P., Laurent, J., 2003. The role played by viruses in the evolution of their hosts: a view based on informational protein phylogenies. Research Microbiology 154, 237-243. https://doi.org/10.1016/S0923-2508(03)00066-4
- Koonin, E.V., Dolja, V.V., 2013. A virocentric perspective on the evolution of life. Curr Opinion Virol 3, 546-557. http://doi.org/10.1016/j.coviro.2013.06.008
- [10] Enard, D., Cai, L., Gwennap, C., Petrov, D.A., 2016. Viruses are a dominant driver of protein adaptation in mammals. eLife 5, e12469. http://doi.org/10.7554/eLife.12469.001
- [11] Baranowski, E., Ruiz-Jarabo, C.M., Pariente, N., Verdaguer, N., Domingo, E., 2003. Evolution of cell recognition by viruses: a source of biological novelty with medical implications. Advances Virus Res 62, 19-111. https://doi.org/10.1016/S0065-3527(03)62002-6
- [12] Ng, W.M., Stelfox, A.J., Bowden, T.A., 2020. Unraveling virus relationships by structure-based phylogenetic classification. Virus Evol 6, veaa003. https://doi.org/10.1093/ve/veaa003
- [13] Ahola, T., Karlin, D.G., 2015. Sequence analysis reveals a conserved extension in the capping enzyme of the alphavirus supergroup, and a homologous domain in nodaviruses. Biol Direct 10, 16. https://doi.org/10.1186/s13062-015-0050-0
- [14] Gorbalenya, A.E., Baker, S.C., Baric, R.S., de Groot, R.J., Drosten, C., Gulyaeva, A.A., et al., 2020. The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5, 536-544. https://doi.org/10.1038/s41564-020-0695-z
- [15] Jaimes, J.A., André, N.M., Chappie, J.S., Millet, J.K., Whittaker, G.R., 2020. Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop. J Mol Biol 432, 3309-3325. https://doi.org/10.1016/j.jmb.2020.04.009
- [16] Masters, P.S., 2006. The molecular biology of coronaviruses. Adv Virus Res 66, 193-292. https://doi.org/10.1016/S0065-3527(06)66005-3
- [17] Cheng, V.C.C., Lau, S.K.P., Woo, P.C.Y., Yuen, K.Y., 2007. Severe acute respiratory syndrome coro-

navirus as an agent of emerging and reemerging infection. Clinical Microbiol Rev 20, 660-694. https://doi.org/10.1128/CMR.00023-07

- [18] Su, S., Wong, G., Shi, W., Liu, J., Lai, A.C.K., Zhou, J., et al., 2016. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24, 490-502. http://doi.org/10.1016/j.tim.2016.03.003
- [19] Li, F., 2016. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 3, 237-261. https://doi.org/10.1146/annurev-virology-110615-042301
- [20] Sanjuán, R., Domingo-Calap, P., 2016. Mechanisms of viral mutation. Cell Mol Life Sci 73, 4433-4448. https://doi.org/10.1007/s00018-016-2299-6
- [21] Lau, S.K.P., Woo, P.C.Y., Li, K.S.M., Huang, Y., Wang, M., Lam, C.S.F., et al., 2007. Complete genome sequence of bat coronavirus HKU2 from chinese horseshoe bats revealed a much smaller spike gene with a different evolutionary lineage from the rest of the genome. Virol 367, 428-439. https://doi.org/10.1016/j.virol.2007.06.009
- [22] Woo, P.C.Y., Lau, S.K.P., Lam, C.S.F., Lau, C.C.Y., Tsang, A.K.L., Lau, J.H.N., et al., 2012. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 86, 3995-4008. http://doi.org/10.1128/JVI.06540-11
- [23] Beniac, D.R., Andonov, A., Grudeski, E., Booth, T.F., 2006. Architecture of the SARS coronavirus prefusion spike. Nature Struct Mol Biol 13, 751-752. http://doi.org/10.1038/nsmb1123
- [24] Li, F., 2012. Evidence for a common evolutionary origin of coronavirus spike protein receptor-binding subunits. J Virol 86, 2856-2858. http://doi.org/10.1128/JVI.06882-11
- [25] Song, W., Gui, M., Wang, X., Xiang, Y., 2018. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog 14, e1007236. https://doi.org/10.1371/journal.ppat.1007236
- [26] Belouzard, S., Millet, J.K., Licitra, B.N., Whittaker, G.R., 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4, 1011-1033. https://doi.org/10.3390/v4061011
- [27] Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., et al., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280. https://doi.org/10.1016/j.cell.2020.02.052
- [28] Letko, M., Marzi, A., Munster, V., 2020. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiol 5, 562-569. https://doi.org/10.1038/s41564-020-0688-y
- [29] Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D., 2020. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 180, 281-292. https://doi.org/10.1016/j.cell.2020.02.058.
- [30] Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G., et al., 2008. SARS coronavirus entry into host cells through a novel clathrin- and caveolaeindependent endocytic pathway. Cell Res 18, 290-301.

https://doi.org/10.1038/cr.2008.15

- [31] Wang, S., Guo, F., Liu, K., Wang, H., Rao, S., Yang, P., et al., 2008. Endocytosis of the receptorbinding domain of SARS-CoV spike protein together with virus receptor ACE2. Virus Research 136, 8-15. https://doi.org/10.1016/j.virusres.2008.03.004
- [32] Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., et al., 2017. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nature Commun 8, 15092. https://doi.org/10.1038/ncomms15092
- [33] Milewska, A., Nowak, P., Owczarek, K., Szczepanski, A., Zarebski, M., Hoang, A., et al., 2018. Entry of human coronavirus NL63 into the cell. J Virol 92, e01933-17. https://doi.org/10.1128/JVI.01933-17
- [34] Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., et al., 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune crossreactivity with SARS-CoV. Nature Commun 11, 1620. https://doi.org/10.1038/s41467-020-15562-9
- [35] Yang, Y., Du, L., Liu, C., Wang, L., Ma, C., Tang, J., et al., 2014. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci USA 111, 12516-12521. http://www.pnas.org/cgi/doi/10.1073/pnas.1405889111
- [36] Li, F., 2015. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol 89, 1954-1964. http://dx.doi.org/10.1128/JVI.02615-14
- [37] Weiss, S.R., Navas-Martin, S., 2005. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69, 635-664. https://doi.org/10.1128/MMBR.69.4.635-664.2005
- [38] Cui, J., Li, F., Shi, Z.-L., 2019. Origin and evolution of pathogenic coronaviruses. Nature Rev Microbiol 17, 181-192. https://doi.org/10.1038/s41579-018-0118-9
- [39] Li, W., Zhang, C., Sui, J., Kuhn, J.H., Moore, M.J., Luo, S., et al., 2005. Receptor and viral determinants of SARScoronavirus adaptation to human ACE2. EMBO J 24, 1634-1643. https://doi.org/10.1038/sj.emboj.7600640
- [40] Wan, Y., Shang, J., Graham, R., Baric, R.S., Li, F., 2020. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 94, e00127-20. https://doi.org/10.1128/JVI.00127-20
- [41] Li, F., Farzan, M., Harrison, S.C., 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864-1868. https://doi.org/10.1126/science.1113611
- [42] Wu, K., Peng, G., Wilken, M., Geraghty, R.J., Li, F., 2012. Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J Biol Chem 287, 8904-8911. https://doi.org/10.1074/jbc.M111.325803.
- [43] Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., et al., 2020. Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor. Nature 581, 215-228. https://doi.org/10.1038/s41586-020-2180-5.
- [44] He, J., Tao, H., Yan, Y., Huang, S.-Y., Xiao, Y., 2020. Molecular mechanism of evolution and human infection with SARS-CoV-2. Viruses 12, 428. https://doi:10.3390/v12040428

- [45] Pickart, C.M., Cohen, R.E., 2004. Proteasomes and their kin: proteases in the machine age. Nature Rev Mol Cell Biol 5, 177-187. https://doi.org/10.1038/nrm1336
- [46] Finley, D., 2009. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 78, 477-513. https://doi.org/10.1146/annurev.biochem.78.081507.101607
- [47] Dieckmann, T., Withers-Ward, E.S., Jarosinski, M.A., Liu, C.-F., Chen, I.S.Y., Feigon, J., 1998. Structure of a human DNA repair protein UBA domain that interacts with HIV-1 Vpr. Nature Struct Biol 5, 1042-1047. https://doi.org/10.1038/4220
- [48] Wilkinson, C.R.M., Seeger, M., Hartmann-Petersen, R., Stone, M., Wallace, M., Semple, C., et al., 2001. Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nature Cell Biol 3, 939-943. https://doi.org/10.1038/ncb1001-939
- [49] Bertolaet, B.L., Clarke, D.J., Wolff, M., Watson, M., Henze, M., Divita, G., et al., 2001. UBA domains mediate protein-protein interactions between two DNA damage-inducible proteins. J Mol Biol 313, 955-963. https://doi.org/10.1006/jmbi.2001.5105
- [50] Madura, K., 2002. The ubiquitin-associated (UBA) domain: On the path from prudence to prurience Cell Cycle 1, 235-244. https://doi.org/10.4161/cc.1.4.130
- [51] Raasi, S., Varadan, R., Fushman, D., Pickart, C.M., 2005. Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nature Struct Mol Biol 12, 708-714. https://doi.org/10.1038/nsmb962
- [52] Long, J., Gallagher, T.R.A., Cavey, J.R., Sheppard, P.W., Ralston, S.H., Layfield, R., et al., 2008. Ubiquitin recognition by the ubiquitin-associated domain of p62 involves a novel conformational switch. J Biol Chem 283, 5427-5440. https://doi.org/10.1074/jbc.M704973200
- [53] Tse, M.K., Hui, S.K., Yang, Y., Yin, S.-T., Hu, H.-Y., Zou, B., et al., 2011. Structural analysis of the UBA domain of X-linked inhibitor of apoptosis protein reveals different surfaces for ubiquitinbinding and self-association. PLoS ONE 6, e28511. https://doi.org/10.1371/journal.pone.0028511
- [54] Cabe, M., Rademacher, D.J., Karlsson, A.B., Cherukuri, S., Bakowska, J.C., 2018. PB1 and UBA domains of p62 are essential for aggresome-like induced structure formation. Biochem Biophys Res Commun 503, 2306-2311. https://doi.org/10.1016/j.bbrc.2018.06.153
- [55] Geetha, T., Wooten, M.W., 2002. Structure and functional properties of the ubiquitin binding protein p62. FEBS Lett 512, 19-24. https://doi.org/10.1016/S0014-5793(02)02286-X
- [56] Mueller, T.D., Feigon, J., (2002). Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. J Mol Biol 319, 1243-1255.
- [57] Qu, X.-X., Hao, P., Song, X.-J., Jiang, S.-M., Liu, Y.-X., Wang, P.-G., et al., 2005. Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. J Biol Chem 280, 29588-29595. https://doi:10.1074/jbc.M500662200
- [58] Sobolev, V., Sorokine, A., Prilusky, J., Abola, E.E., Edelman, M., 1999. Automated analysis of interatomic contacts in proteins. Bioinformatics, 15, 327-332.
- [59] Wimley, W.C., White, S.H., 1996. Experimentally determined hydrophobicity scale for proteins at mem-

- [60] Yi, C., Sun, X., Ye, J., Ding, L., Liu, M., Yang, Z., et al., 2020. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol 17, 621-630. https://doi.org/10.1038/s41423-020-0458-z
- [61] Zhang, N., Chen, Y., Lu, H., Zhao, F., Alvarez, R.V., Goncearenco, A., Panchenko, A.R., Li, M., 2020. MutaBind2: Predicting the Impacts of Single and Multiple Mutations on Protein-Protein Interactions. iScience 23, 100939.
- [62] Minghui, L., Simonetti, F.L., Goncearenco, A., Panchenko, A.R., 2016. MutaBind estimates and interprets the effects of sequence variants on protein–protein interactions. Nucl Ac Res 44, W494-W501.
- [63] Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A.A., Zhu, G., Epstein, J.H., et al., 2013. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535-538. https://doi:10.1038/nature12711
- [64] Hu, B., Zeng, L.-P., Yang, X.-L., Ge, X.-Y., Zhang, W., Li, B., et al., 2017. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog 13, e1006698. https://doi.org/10.1371/journal.ppat.1006698
- [65] Yang, X.-L., Hu, B., Wang, B., Wang, M.-N., Zhang, Q., Zhang, W., et al., 2016. Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus. J Virol 90, 3253-3256. https://doi:10.1128/JVI.02582-15
- [66] Gralinski, L.E., Menachery, V.D., 2020. Return of the Coronavirus: 2019-nCoV. Viruses 12, 135. https://doi:10.3390/v12020135
- [67] Armijos-Jaramillo, V., Yeager, J., Muslin, C., Perez-Castillo, Y., 2020. SARS-CoV-2, an evolutionary perspective of interaction with human ACE2 reveals undiscovered amino acids necessary for complex stability. bioRxiv preprint https://doi.org/10.1101/2020.03.21.001933
- [68] Hoffmann, M., Müller M.A., Drexler, J.F., Glende, J., Erdt, M., Gützkow, T., et al., 2013. Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses. PLoS ONE 8, e72942. https://doi:10.1371/journal.pone.0072942
- [69] Zhang, T., Wu, Q., Zhang, Z., 2020. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol 30, 1346-1351. https://doi.org/10.1016/j.cub.2020.03.022
- [70] Li, F., 2008. Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. J Virol 82, 6984-6991. https://doi:10.1128/JVI.00442-08

- [71] Lam, T.T.-Y., Shum, M.H.-H., Zhu, H.-C., Tong, Y.-G., Ni, X.-B., Liao, Y.-S., et al., 2020. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 583, 282-285. https://doi:10.1038/s41586-020-2169-0
- [72] Hofmann, H., Pyrc, K., van der Hoek, L., Geier, M., Berkhout, B., Pöhlmann, S., 2005. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA 102, 7988-7993. https://doi:10.1073/pnas.0409465102
- [73] Hofmann, H., Simmons, G., Rennekamp, A.J., Chaipan, C., Gramberg, T., Heck, E., et al., 2006. Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J Virol 80, 8639-8652. https://doi:10.1128/JVI.00560-06
- [74] Milewska, A., Zarebski, M., Nowak, P., Stozek, K., Potempa, J., Pyrc, K., 2014. Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol 88, 13221-13230. https://doi.org/10.1128/JVI.02078-14
- [75] Glowacka, I., Bertram, S., Herzog, P., Pfefferle, S., Steffen, I., Muench, M.O., et al., 2010. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol 84, 1198-1205. https://doi:10.1128/JVI.01248-09
- [76] Wu, K., Li, W., Peng, G., Li, F., 2009. Crystal structure of NL63 respiratory coronavirus receptorbinding domain complexed with its human receptor. Proc Natl Acad Sci USA 106, 19970-19974. https://doi.org/10.1073/pnas.0908837106
- [77] Li, W., Sui, J., Huang, I.-C., Kuhn, J.H., Radoshitzky, S.R., Marasco, W.A., et al., 2007. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology 367, 367-374. https://doi:10.1016/j.virol.2007.04.035
- [78] Lin, H.-X., Feng, Y., Wong, G., Wang, L., Li, B., Zhao, X., et al., 2008. Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction. J Gen Virol 89, 1015-1024. https://doi:10.1099/vir.0.83331-0
- [79] Lin, H.-X., Feng, Y., Tu, X., Zhao, X., Hsieh, C.-H., Griffin, L., et al., 2011. Characterization of the spike protein of human coronavirus NL63 in receptor binding and pseudotype virus entry. Virus Res 160, 283-293. https://doi:10.1016/j.virusres.2011.06.029
- [80] Yves Dehouck, Y., Kwasigroch, J.M., Rooman, M., Gilis, D., 2013. BeAtMuSiC: prediction of changes in protein-protein binding affinity on mutations Nucleic Acids Res 41, W333-W339.

Name	Spike Glycoprotein GenBank	Name	Spike Glycoprotein GenBank	Name	Spike Glycoprotein GenBank
SARS-CoV-Tor2	AAP41037.1	SARS-CoV PC4-115	AAV49719.1	Rhinolophus affinis CoV LYRa3 (SARS-like)	AHX37569.1
SARS-CoV BJ01	AAP30030.1	SARS-CoV PC4-145	AAV49721.1	Rhinolophus affinis CoV LYRa11 (SARS-like)	AHX37558.1
SARS-CoV CUHK-W1	AAP13567.1	SARS-CoV PC4-241	AAV49723.1	Bat SARS-like CoV Rs3367	AGZ48818.1
SARS-CoV Urbani	AAP13441.1	SARS-CoV civet014	AAU04661.1	Bat SARS-like CoV Rs4874	ATO98205.1
SARS-CoV Frankfurt-1	AAP33697.1	SARS-CoV PC4-137	AAV49720.1	Bat SARS-like CoV WIV1	AGZ48828.1
SARS-CoV CUHK-AG01	AAP94737.1	SARS-CoV civet020	AAU04664.1	SARS-like CoV WIV16	ALK02457.1
SARS-CoV TW6	AAR87567.1	SARS-CoV PC4-127	AAU93318.1	Bat SARS CoV RaTG13	QHR63300.2
SARS-CoV TW11	AAR87512.1	SARS-CoV B039	AAV97993.1	Bat SARS-like CoV Rs7327	ATO98218.1
SARS-CoV HKU-39849	ADC35483.1	SARS-CoV PC4-205	AAU93319.1	Bat SARS-like CoV Rs9401	ATO98231.1
SARS-CoV-2 Wuhan-Hu-1	QHD43416.1	SARS-CoV PC4-199	AAV49722.1	CoV BtRs-BetaCoV/YN2018B	QDF43825.1
SARS-CoV-2 CA-CDC-0139	QJV58828.1	SARS-CoV civet010	AAU04649.1	Bat SARS-like CoV RsSHC014	AGZ48806.1
SARS-CoV-2 France	QJT72590.1	SARS-CoV civet019	AAU04662.1	Bat SARS-like CoV Rs4084	ATO98132.1
SARS-CoV-2 WHUHnCoV011	QIU82034.1	SARS-CoV A022	AAV91631.1	Bat SARS-like CoV Rs4231	ATO98157.1
SARS-CoV-2 CA-CZB-1248	QKE49268.1	Civet SARS-CoV 007/2004	AAU04646.1	SARS-CoV strain BtKY72	APO40579.1
SARS-CoV-2 CA-CZB-1033	QJQ38756.1	SARS-CoV A001	AAV97984.1	SARS-like CoV BatCoV/BB9904/BGR/2008	ALJ94036.1
SARS-CoV-2 France/10070SK	QJT73010.1	PCoV GX-P2V	QIQ54048.1	Bat CoV BM48-31/BGR/2008 (SARS-like)	ADK66841.1
SARS-CoV-2 CA-CZB0103	QJE38330.1	PCoV GX-P4L	QIA48614.1	CoV BtRI-BetaCoV/SC2018	QDF43815.1
SARS-CoV-2 BetaCoV/Wuhan/IPBCAMS-WH-05	QHU36864.1	PCoV GX-P5L	QIA48632.1	BtRs-BetaCoV/HuB2013	AIA62310.1
SARS-CoV-2 CruiseA-18	QII57278.1			Bat SARS-CoV HKU3-1	AAY88866.1
SARS-CoV-2 CA-CZB-1105	QJS54754.1			Bat SARS-like CoV bat-SL-CoVZC45	AVP78031.1
				Bat SARS-like CoV bat-SL-CoVZXC21	AVP78042.1
				Bat SARS-CoV Rf1/2004	ABD75323.1
				Bat SARS-like CoV Rf4092	ATO98145.1
				Bat CoV Anlong-103	ARI44799.1
				Bat CoV Anlong-112	ARI44804.1
				Bat SARS-CoV Rp3/2004	AAZ67052.1
				CoV BtRs-BetaCoV/YN2018C	QDF43830.1
				Bat CoV Rp/Shaanxi2011	AGC74165.1
				Bat SARS-CoV Rm1	ABD75332.1

Table S1: GenBank accession numbers for the coronavirus sequences analysed in this study.